AU2001234741A1 - Integrin antagonists - Google Patents

Integrin antagonists

Info

Publication number
AU2001234741A1
AU2001234741A1 AU2001234741A AU3474101A AU2001234741A1 AU 2001234741 A1 AU2001234741 A1 AU 2001234741A1 AU 2001234741 A AU2001234741 A AU 2001234741A AU 3474101 A AU3474101 A AU 3474101A AU 2001234741 A1 AU2001234741 A1 AU 2001234741A1
Authority
AU
Australia
Prior art keywords
integrin antagonists
integrin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234741A
Inventor
Mary Beth Carter
Julio H. Cuervo
Zhongli Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AU2001234741A1 publication Critical patent/AU2001234741A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
AU2001234741A 2000-02-04 2001-02-01 Integrin antagonists Abandoned AU2001234741A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18022500P 2000-02-04 2000-02-04
US60180225 2000-02-04
PCT/US2001/003347 WO2001056994A1 (en) 2000-02-04 2001-02-01 Integrin antagonists

Publications (1)

Publication Number Publication Date
AU2001234741A1 true AU2001234741A1 (en) 2001-08-14

Family

ID=22659685

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234741A Abandoned AU2001234741A1 (en) 2000-02-04 2001-02-01 Integrin antagonists

Country Status (2)

Country Link
AU (1) AU2001234741A1 (en)
WO (1) WO2001056994A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1847534E (en) 2001-12-11 2011-08-01 Kyowa Hakko Kirin Co Ltd Thiadiazoline derivatives for treating cancer
EP1546089A2 (en) 2002-08-09 2005-06-29 TransTech Pharma Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
CN101787000B (en) 2003-04-18 2011-08-03 协和发酵麒麟株式会社 M-stage kinesin inhibitor
AU2004251754A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
WO2005014534A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
WO2006137490A1 (en) 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for restenosis
US8324257B2 (en) 2006-10-03 2012-12-04 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
ES2856125T3 (en) * 2016-02-05 2021-09-27 Ea Pharma Co Ltd Sulfonamide derivative and pharmaceutical composition containing the same
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
EP3873605A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
KR20240015737A (en) 2018-10-30 2024-02-05 길리애드 사이언시즈, 인코포레이티드 Quinoline derivatives as alpha4beta7 integrin inhibitors
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU758939B2 (en) * 1998-06-30 2003-04-03 Pfizer Products Inc. Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases

Also Published As

Publication number Publication date
WO2001056994A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU3213799A (en) Integrin antagonists
AU2001210928A1 (en) Polypropylene card construction
AU2002341834A1 (en) Antagonists
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2001255798A1 (en) Glucagon antagonists
AU7315800A (en) Mch antagonists
AU2001251485A1 (en) Container
AU2001258096A1 (en) Container
AU2001296869A1 (en) Container
AU2001267516A1 (en) Container
AU2002235224A1 (en) Muscarinic antagonists
AU2001288040A1 (en) Homeostasis-maintaining agents
AU2002214284A1 (en) Anti-helicobacterial agents
AU2001234741A1 (en) Integrin antagonists
AU2001231088A1 (en) Mutli-purpose container
AU2001279143A1 (en) Metlblown web
AU2001269441A1 (en) Container
AU2001239773A1 (en) Baroplastic materials
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU2541000A (en) Beta-phenylalanine derivatives as integrin antagonists
AU2001238138A1 (en) Body-cooling container
AU2001285748A1 (en) Integrin ligands
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists
AU2001293131A1 (en) Hydroxy acid integrin antagonists